News

Patients with TP53 wild-type endometrial cancer experienced a median progression-free survival of 27.4 months vs 5.2 months with placebo.

Interpretation devices may have a useful application in cancer care.

The FDA has approved LeukoStrat CDx FLT3, a companion diagnostic, to help identify patients with FLT3-ITD–positive acute myeloid leukemia who are eligible to receive quizartinib.

Oncology nurses must know about disease symptoms and patient comorbidities when treating individuals with myeloproliferative neoplasms.

The investigator-assessed progression-free survival was 9.0 months with sugemalimab plus chemotherapy arm vs 4.9 months with placebo plus chemotherapy.

An update to the American Society of Clinical Oncology guidelines state that all patients with cancer who are older than 65 years should receive a geriatric assessment.

Patients who listen to music while receiving chemotherapy may experience lower levels of distress.

Patients with MPNs should be taught that ‘no symptom is too small to bring to the attention of your nurse.’

CB-010 led to a 94% overall response rate among 16 patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

At a follow-up of 6.1 years, patients who received regional nodal irradiation did not achieve significant reductions in locoregional recurrence rates compared to those who received surgery alone.

ASP-1929, an antibody-dye conjugate, plus pembrolizumab, induced a 29.4% overall response rate in patients with recurrent or metastatic head and neck squamous cell carcinoma.

The phase 3 CheckMate-901 trial met its dual primary end points for progression-free survival and overall survival.

Patients with EGFR-mutated non–small cell lung cancer and MET positivity may derive greater benefit from amivantamab plus lazertinib than patients who are MET-negative.

Quizartinib has been approved by the FDA for use with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy after consolidation chemotherapy, to treat adults with newly diagnosed acute myeloid leukemia that is FLT3-ITD positive, as detected by an FDA-approved test.

Patients with synchronous metastatic renal cell carcinoma experienced worse outcomes with first line immune-checkpoint inhibitors-based combinations vs those with metachronous disease.

Third-line lisocabtagene maraleucel induced a response in 97% of patients with relapsed or refractory follicular lymphoma.

Lazertinib reduced the risk of progression by 55% in patients with EGFR-mutated advanced non–small cell lung cancer compared with gefitinib.

Final overall survival analysis highlights benefit of lenvatinib plus pembrolizumab vs sunitinib in the treatment of patients with advanced renal cell carcinoma.

Trastuzumab deruxtecan elicited a confirmed objective response rate of 42% in patients with HER2-positive gastric or gastroesophageal junction cancer, according to findings from the phase 2 DESTINY-Gastric02 trial.

Adjuvant pembrolizumab improved disease-free survival outcomes vs placebo across subgroups of patients with clear cell renal cell carcinoma in the KEYNOTE-564 study.

The onset of skeletal events and events that affect health-related quality of life were delayed with the addition of lutetium Lu 177 vipivotide tetraxetan to standard of care for patients with metastatic castration-resistant prostate cancer.

Among 32 patients, 66% experienced a prostate-specific antigen response rate of at least 50%.

Findings from the phase 1b cohort of the KRYSTAL-1 trial underscore the intracranial permeation of the KRAS G12C inhibitor adagrasib for patients with non–small cell lung cancer with untreated central nervous system metastases.

Intensified doxorubicin, bleomycin, vinblastine, dacarbazine, and granulocyte colony–stimulating factor (ABVD) was associated with a 56% reduction in the relative risk of 3-year progression, relapse, or death.

Glofitamab monotherapy led to a 63.6% overall response rate in heavily pretreated patients with Richter syndrome.

By 3 months postsurgery, most older patients with colon or rectal cancer had achieved functional recovery.

Patients with oropharyngeal squamous cell carcinoma who received primary radiotherapy or surgery demonstrated similar long-term patient-reported outcomes.

On-pathway regimens are associated with lower costs, and slightly higher emergency department visits and adverse event rates in cancer care.

The rate of pathologic complete responses with enfortumab vedotin was 36.4% among patients with muscle-invasive bladder.

Pirtobrutinib was associated with a 19.6-month median progression-free survival in patients with heavily pretreated chronic lymphocytic leukemia and small lymphocytic lymphoma.